Which has stronger earnings & valuation, AZTA or SHC?

Sotera Health has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Azenta $593.82M 2.91 -$55.76M -$2.76 N/A Sotera Health $1.16B 4.50 $77.94M $0.57 32.19

Is AZTA or SHC more profitable?

Sotera Health has a net margin of 13.44% compared to Azenta's net margin of -20.63%. Sotera Health's return on equity of 40.12% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Azenta -20.63% 1.18% 0.97% Sotera Health 13.44% 40.12% 7.55%

Does the media refer more to AZTA or SHC?

In the previous week, Azenta had 3 more articles in the media than Sotera Health. MarketBeat recorded 4 mentions for Azenta and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.59 beat Azenta's score of 0.36 indicating that Sotera Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sotera Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADPT or AZTA?

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Azenta. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 4 mentions for Azenta. Adaptive Biotechnologies' average media sentiment score of 0.52 beat Azenta's score of 0.36 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AZTA or ALMR?

In the previous week, Azenta had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Azenta and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.88 beat Azenta's score of 0.36 indicating that Alamar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, FTRE or AZTA?

Azenta has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.72B 0.69 -$986.20M -$0.91 N/A Azenta $593.82M 2.91 -$55.76M -$2.76 N/A

Is FTRE or AZTA more profitable?

Fortrea has a net margin of -3.18% compared to Azenta's net margin of -20.63%. Fortrea's return on equity of 10.72% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Azenta -20.63% 1.18% 0.97%

Does the media prefer FTRE or AZTA?

In the previous week, Fortrea had 4 more articles in the media than Azenta. MarketBeat recorded 8 mentions for Fortrea and 4 mentions for Azenta. Fortrea's average media sentiment score of 0.50 beat Azenta's score of 0.36 indicating that Fortrea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, MRVI or AZTA?

Azenta has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maravai LifeSciences $185.74M 10.94 -$130.77M -$0.52 N/A Azenta $593.82M 2.91 -$55.76M -$2.76 N/A

Does the media prefer MRVI or AZTA?

In the previous week, Azenta had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 4 mentions for Azenta and 2 mentions for Maravai LifeSciences. Azenta's average media sentiment score of 0.36 beat Maravai LifeSciences' score of 0.00 indicating that Azenta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Azenta 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Azenta (AZTA) Competitors

$38.66 +4.18 (+12.13%)

As of 12:43 PM Eastern

Compare

AZTA vs. SHC, ADPT, ALMR, FTRE, and MRVI

Should you buy Azenta stock or one of its competitors? Azenta's main competitors and comparable companies include Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), Fortrea (FTRE), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Azenta compare to Sotera Health?

Azenta (NASDAQ:AZTA) and Sotera Health (NASDAQ:SHC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Azenta had 3 more articles in the media than Sotera Health. MarketBeat recorded 4 mentions for Azenta and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.59 beat Azenta's score of 0.36 indicating that Sotera Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sotera Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health has a net margin of 13.44% compared to Azenta's net margin of -20.63%. Sotera Health's return on equity of 40.12% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Sotera Health	13.44%	40.12%	7.55%

Azenta presently has a consensus price target of $41.20, suggesting a potential upside of 4.57%. Sotera Health has a consensus price target of $21.50, suggesting a potential upside of 17.17%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts clearly believe Sotera Health is more favorable than Azenta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Azenta has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market.

99.1% of Azenta shares are held by institutional investors. Comparatively, 91.0% of Sotera Health shares are held by institutional investors. 10.9% of Azenta shares are held by company insiders. Comparatively, 15.4% of Sotera Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sotera Health has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82M	2.91	-$55.76M	-$2.76	N/A
Sotera Health	$1.16B	4.50	$77.94M	$0.57	32.19

Summary

Sotera Health beats Azenta on 14 of the 16 factors compared between the two stocks.

How does Azenta compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Azenta (NASDAQ:AZTA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Adaptive Biotechnologies has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, Azenta has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Azenta. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 4 mentions for Azenta. Adaptive Biotechnologies' average media sentiment score of 0.52 beat Azenta's score of 0.36 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adaptive Biotechnologies currently has a consensus price target of $28.94, indicating a potential upside of 3.14%. Azenta has a consensus price target of $41.20, indicating a potential upside of 4.57%. Given Azenta's higher possible upside, analysts plainly believe Azenta is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Azenta has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	16.17	-$59.50M	-$0.41	N/A
Azenta	$593.82M	2.91	-$55.76M	-$2.76	N/A

Azenta has a net margin of -20.63% compared to Adaptive Biotechnologies' net margin of -20.73%. Azenta's return on equity of 1.18% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Azenta	-20.63%	1.18%	0.97%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Adaptive Biotechnologies and Azenta tied by winning 8 of the 16 factors compared between the two stocks.

How does Azenta compare to Alamar Biosciences?

Azenta (NASDAQ:AZTA) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Alamar Biosciences has a net margin of 0.00% compared to Azenta's net margin of -20.63%. Azenta's return on equity of 1.18% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Alamar Biosciences	N/A	N/A	N/A

99.1% of Azenta shares are held by institutional investors. 10.9% of Azenta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alamar Biosciences has lower revenue, but higher earnings than Azenta. Alamar Biosciences is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82M	2.91	-$55.76M	-$2.76	N/A
Alamar Biosciences	$74.21M	32.18	-$29.82M	-$1.96	N/A

Azenta currently has a consensus target price of $41.20, indicating a potential upside of 4.57%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential downside of 7.61%. Given Azenta's higher possible upside, equities analysts plainly believe Azenta is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Azenta had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Azenta and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 0.88 beat Azenta's score of 0.36 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Azenta beats Alamar Biosciences on 8 of the 13 factors compared between the two stocks.

How does Azenta compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Fortrea has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Azenta has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

99.1% of Azenta shares are owned by institutional investors. 0.7% of Fortrea shares are owned by insiders. Comparatively, 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Fortrea has a net margin of -3.18% compared to Azenta's net margin of -20.63%. Fortrea's return on equity of 10.72% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Azenta	-20.63%	1.18%	0.97%

Fortrea currently has a consensus price target of $22.00, indicating a potential upside of 11.20%. Azenta has a consensus price target of $41.20, indicating a potential upside of 4.57%. Given Fortrea's higher possible upside, research analysts plainly believe Fortrea is more favorable than Azenta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Azenta has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.69	-$986.20M	-$0.91	N/A
Azenta	$593.82M	2.91	-$55.76M	-$2.76	N/A

In the previous week, Fortrea had 4 more articles in the media than Azenta. MarketBeat recorded 8 mentions for Fortrea and 4 mentions for Azenta. Fortrea's average media sentiment score of 0.50 beat Azenta's score of 0.36 indicating that Fortrea is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortrea beats Azenta on 10 of the 16 factors compared between the two stocks.

How does Azenta compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Azenta (NASDAQ:AZTA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Azenta has a net margin of -20.63% compared to Maravai LifeSciences' net margin of -37.07%. Azenta's return on equity of 1.18% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Azenta	-20.63%	1.18%	0.97%

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Maravai LifeSciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Azenta has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Azenta has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.94	-$130.77M	-$0.52	N/A
Azenta	$593.82M	2.91	-$55.76M	-$2.76	N/A

In the previous week, Azenta had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 4 mentions for Azenta and 2 mentions for Maravai LifeSciences. Azenta's average media sentiment score of 0.36 beat Maravai LifeSciences' score of 0.00 indicating that Azenta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Azenta	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maravai LifeSciences currently has a consensus price target of $6.83, suggesting a potential downside of 12.71%. Azenta has a consensus price target of $41.20, suggesting a potential upside of 4.57%. Given Azenta's stronger consensus rating and higher possible upside, analysts plainly believe Azenta is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Azenta beats Maravai LifeSciences on 14 of the 16 factors compared between the two stocks.

Get Azenta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZTA vs. The Competition

Export

Metric	Azenta	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.74B	$10.67B	$7.12B	$13.24B
Dividend Yield	N/A	1.45%	2.53%	15.88%
P/E Ratio	-14.40	75.19	274.21	26.08
Price / Sales	2.91	110.20	607.93	92.41
Price / Cash	19.25	27.76	77.38	51.25
Price / Book	1.05	6.83	10.92	6.30
Net Income	-$55.76M	$57.48B	$3.50B	$361.41M
7 Day Performance	15.82%	2.23%	-2.09%	-1.55%
1 Month Performance	24.18%	7.39%	-6.33%	-3.80%
1 Year Performance	25.12%	35.05%	9.10%	2.92%

Azenta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZTA Azenta	1.0258 of 5 stars	$38.66 +12.1%	$41.20 +6.6%	+9.2%	$1.69B	$593.82M	N/A	2,900	High Trading Volume
SHC Sotera Health	3.8008 of 5 stars	$18.70 -0.2%	$21.50 +15.0%	+11.9%	$5.35B	$1.16B	32.81	3,000
ADPT Adaptive Biotechnologies	1.7903 of 5 stars	$27.86 -2.6%	$25.92 -7.0%	+88.0%	$4.57B	$276.98M	N/A	624	Analyst Forecast
ALMR Alamar Biosciences	1.6405 of 5 stars	$35.05 +0.6%	$31.80 -9.3%	N/A	$2.42B	$74.21M	N/A	222
FTRE Fortrea	2.9526 of 5 stars	$20.02 +0.5%	$22.00 +9.9%	+103.8%	$1.90B	$2.72B	N/A	14,300	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AZTA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Azenta (AZTA) Competitors

AZTA vs. SHC, ADPT, ALMR, FTRE, and MRVI

How does Azenta compare to Sotera Health?

Summary

How does Azenta compare to Adaptive Biotechnologies?

Summary

How does Azenta compare to Alamar Biosciences?

Summary

How does Azenta compare to Fortrea?

Summary

How does Azenta compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTA vs. The Competition

Azenta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Azenta (AZTA) Competitors

AZTA vs. SHC, ADPT, ALMR, FTRE, and MRVI

How does Azenta compare to Sotera Health?

Does the media refer more to AZTA or SHC?

Is AZTA or SHC more profitable?

Do analysts rate AZTA or SHC?

Which has more volatility and risk, AZTA or SHC?

Do insiders and institutionals have more ownership in AZTA or SHC?

Which has stronger earnings & valuation, AZTA or SHC?

Summary

How does Azenta compare to Adaptive Biotechnologies?

Which has more volatility and risk, ADPT or AZTA?

Does the media prefer ADPT or AZTA?

Do analysts prefer ADPT or AZTA?

Which has higher earnings and valuation, ADPT or AZTA?

Is ADPT or AZTA more profitable?

Do insiders & institutionals believe in ADPT or AZTA?

Summary

How does Azenta compare to Alamar Biosciences?

Is AZTA or ALMR more profitable?

Do insiders and institutionals hold more shares of AZTA or ALMR?

Which has higher valuation and earnings, AZTA or ALMR?

Do analysts prefer AZTA or ALMR?

Does the media prefer AZTA or ALMR?

Summary

How does Azenta compare to Fortrea?

Which has more volatility & risk, FTRE or AZTA?

Do institutionals & insiders hold more shares of FTRE or AZTA?

Is FTRE or AZTA more profitable?

Do analysts rate FTRE or AZTA?

Which has better earnings and valuation, FTRE or AZTA?

Does the media prefer FTRE or AZTA?

Summary

How does Azenta compare to Maravai LifeSciences?

Is MRVI or AZTA more profitable?

Do institutionals and insiders have more ownership in MRVI or AZTA?

Which has more volatility and risk, MRVI or AZTA?

Which has preferable earnings and valuation, MRVI or AZTA?

Does the media prefer MRVI or AZTA?

Do analysts rate MRVI or AZTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTA vs. The Competition

Azenta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools